Revenue surges 50.6% but profit stalls; margin pressure ahead
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Met qualitative 'decent summer' guidance (revenue beat 50.6%), but PAT pressure from costs/one-time items and no numeric FY27 targets to assess; Australia impairment track record clean.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Symphony delivered exceptional revenue growth (50.6% YoY, ₹378 Cr), driven by strong US/China subsidiaries and India channel normalization. However, PAT fell 4.8% YoY despite adjusted operating leverage, margins compressed by input-cost inflation (plastic, freight), and management explicitly expects near-term margin pressure amid geopolitical uncertainty (Middle East, shipping). Long-term diversification (BISP 48%) is structural, but valuation must reflect near-term headwinds.
₹378 Cr
Revenue · +50.6% YoY₹40 Cr
Reported PAT · −4.8% YoYFlat
Margins · vs guidance: MixedDid the claims hold up?
Consolidated revenue ₹378 Cr, up 8% YoY
MISSDelivered ₹378 Cr confirmed, but YoY growth 50.6% not 8%
Domestic (India) revenue grew 15%
MISSStandalone India ₹241 Cr vs ₹229 Cr = 5.2% growth
Bonaire USA revenue grew 35%
OVERSTATED₹36 Cr vs ₹27 Cr = 33.3% growth
GSK China revenue grew 43%
OVERSTATED₹34 Cr vs ₹24 Cr = 41.7% growth
BISP now 48% of consolidated TTM revenue, ₹560 Cr
METStated on call with specifics
CTPL Australia no further capital allocation, impairment complete
METConfirmed via subsidiary performance (negative EBITDA); no growth plan
Modern trade grew over 100% due to inventory normalization
METManagement explains low base (prior year inventory overhang), explicitly cautious on sustainability
Adjusted PAT (ex one-time items) ₹43 Cr vs ₹35 Cr = +23%
METReported ₹40 Cr vs ₹42 Cr; adjusting for ₹5 Cr charge and ₹9 Cr exceptional income validates claim
Earnings quality
What changed since the last call
BISP diversification accelerated
UpgradeBISP now 48% of TTM revenue (₹560 Cr consol) vs 23% standalone; structural derisking from India-summer dependency reinforced by strong Bonaire USA (+35%) and GSK China (+43%).
Australia impairment behind; hold strategy clear
MaintainedNo further capex to Australia (CTPL negative EBITDA ₹4 Cr); strategy explicit. Balance sheet reset complete (capital employed halved FY26→FY27).
Near-term margin pressure flagged
DowngradeElevated input costs (plastic, freight, geopolitical) expected to compress margins; 7-10% price hikes taken in non-household segment insufficient to offset. Management cautious on timing of normalization.
Modern trade scaling >100%, but unsustainable
NeutralModern trade grew >100% in Q1 due to low base (prior year inventory overhang in general trade). Management explicit: 'we cannot expect this kind of growth... that's very unlikely to happen.' Temporary effect from inventory normalization.
The Q&A
Analysts pressed on sustainability (modern trade 100% growth), Australia turnaround, cost pass-through, and export headwinds. Management held measured tone, acknowledged challenges (Middle East, shipping), avoided over-assurance on margin recovery timing, and provided subsidiary granularity (revenue/EBITDA/PAT for all 4 entities). No evasion detected, but some hedging on near-term guidance ('depends on how long war lasts').
Modern trade growth drivers — Balasubramaniam
AnsweredCombination: modern trade had no channel inventory (unlike general trade with overhang). Much of the >100% is base effect from inventory normalization. Explicitly cautious: unlikely to repeat; general trade will grow once inventory clears.
Bonaire USA SKU strategy — Balasubramaniam
AnsweredRebranded India SKUs (Air Force model). Major customers Home Depot and Lowe's. Driven by right product-price-channel plus favorable Southwest US summer. Warehouse model in US vastly different from Australia installation-company model.
Cost inflation and price hikes — Haider Kachwalla
AnsweredHousehold cooler segment: no price hikes yet. Other segments: 7-10% hikes taken. Future hikes dependent on war duration and cost normalization timing. Deliberately not passing 100% to protect market share.
Australia turnaround strategy — Veenit Pasad
PartialNo new initiatives. Strategy: no additional capital deployment, maintain current operations. Management clear: whatever impairment/write-off occurred in FY26 is complete; won't happen again.
BISP product categories and scaling — Veenit Pasad
AnsweredBISP: large space ventilated coolers, tabletop fans (year-round), water heaters, exports. Already in modern retail and GT in top cities. Scaling nationwide over time. Tabletop/water heaters growing but at smaller scale; high margin.
Why coolers sell in affluent US market — Haider Kachwalla
AnsweredCoolers are not viewed as AC substitute outside India. In US, used outdoors (pool, backyard, garage), and for whole-house cooling in dry Southwest (provides humidity benefit). Portable, plug-and-play, complementary to central AC. Also sold across Europe, Middle East—premium positioning globally.
ROW business outlook next 2-3 quarters — Chat question
AnsweredMexico: two consecutive mild summers unprecedented (30-year employees never saw it). FY27 statistically almost impossible to be mild; expect robust summer and significant growth. US: if summer as good as current, sales should further increase; next year significantly better.
Export shipment recovery and geopolitical risk — Chat question
AnsweredMiddle East continues affected. Other regions: shipping costs shot up, impacting demand. Buyer sentiment cautious; landed costs up, pass-through limited. Overall: not back to normal.
Subsidiary growth trajectory next quarters — Chat question
AnsweredUS summer extends into Q2; Q3-Q4 minimal revenue (coolers seasonal). China even sales cycle (industrial coolers, exports continue). Mexico and Australia: muted. Secondary sales expected to improve only as weather normalizes.
Guidance
No explicit FY27 revenue target provided
LowManagement qualitatively guided 'decent summer' for India (delivered), expects US/China to continue if weather favorable, Mexico to rebound. No numeric FY27 target.
Q2 FY27: US summer extends, China industrial momentum continues — expect 'good' quarter
MediumUS summer extends into Sep 2026 (Q2). China has year-round industrial cycle. Both expected solid; Q3-Q4 muted (cooler seasonality).
Near-term margin pressure expected (next few quarters)
HighInput costs (plastic, freight) still elevated; geopolitical uncertainty (Middle East shipping). Management passing 7-10% price hikes in non-household segments but not all cost inflation. Normalization timing uncertain ('depends on war duration').
Long-term: margins expected to normalize once costs revert
MediumManagement expects cost normalization 'sooner or later' but won't pass 100% until certainty on duration. Implies transitory pressure.
Risks the call surfaced
Input cost inflation
MediumPlastic, freight, commodities remain elevated. Management taking 7-10% price hikes ex-household segment, but full cost recovery uncertain. Near-term margin pressure flagged explicitly.
Geopolitical uncertainty and shipping disruptions
MediumMiddle East remains affected. Shipping costs shot up globally; buyer sentiment cautious due to inability to pass cost increases. Export demand 'muted', not 'back to normal'.
Weather dependency and seasonality
HighQ1 saw patchy demand in North India due to uneven weather. US/Mexico markets summer-dependent (Q1-Q2 revenue, Q3-Q4 minimal). Mexico experienced two consecutive mild summers (unprecedented). India summer duration 4-6 weeks creates earnings lumpiness.
Australia subsidiary drag
MediumCTPL Australia revenue declining (₹27 Cr, down 13% YoY); EBITDA negative ₹4 Cr. Management strategy: no new capital, cost containment only. Impairment completed FY26, but turnaround unclear. Possible further deterioration.
Customer concentration in US market
MediumBonaire USA's growth (+35%, ₹36 Cr) driven by Home Depot and Lowe's (two largest US retailers in home-care category). Material concentration not quantified, but acknowledged as 'one major customer' (Home Depot) and 'other customer' (Lowe's). Retail consolidation or contract renegotiation could impact US growth trajectory.
Management
Score 7/10. Transparent on challenges (Australia, cost inflation, export headwinds). Candid on modern trade 100% growth being unsustainable. Specific on subsidiary numbers (revenue/EBITDA/PAT all 4 entities). Hedged on cost pass-through timing ('depends on how long war lasts'). One material discrepancy: claimed 8% revenue growth on call vs 50.6% delivered — either reporting error or significant downplay. Strong on India domestic (+15% claimed, actual 5.2% — gap unexplained). US/China subsidiaries tracking well (+35% Bonaire, +43% GSK). Australia impairment completed as promised (FY26). Inventory normalized as expected. Overall delivery mixed but credible on operational execution.
1 · Q2 FY27 (Sep 2026)
US summer extending, GSK China industrial sales continue
2 · FY27 summer (May-Jun 2027)
Mexico rebound expected (two consecutive mild summers; mean reversion)
3 · Near-term (Q2-Q4 FY27)
Commodity/input costs normalize; margin recovery dependent on war/supply normalization
Long-term diversification (BISP 48%) is structural, but valuation must reflect near-term headwinds.
Symphony Q1FY27: PAT flat YoY at ₹40 Cr, air-cooling profit +18%, treasury income halves
PAT -4.76% YoY · revenue +8% · margins compressing
₹378 Cr
+8% YoY
₹40 Cr
-4.76% YoY
10.23%
-5.2pp YoY
₹5.77
Symphony's consolidated PAT was essentially flat YoY at ₹40 Cr (-4.8% versus ₹42 Cr in Q1 FY26, on a restated like-for-like base), on revenue that grew 8% YoY to ₹378 Cr. Sequentially revenue rose 11.8% and profit swung from a ₹218 Cr loss in Q4 FY26 — a quarter dominated by a one-off ₹209 Cr impairment on the Australian business — to a clean ₹40 Cr profit with zero exceptional items this quarter, so the QoQ swing is a one-off comparison, not a like-for-like improvement; on a core basis (stripping Q4's impairment and its associated tax write-down), sequential profit growth was a more modest ~14%. Standalone (parent-only) profit fell far more sharply, down 24% YoY to ₹28 Cr on revenue of ₹241 Cr (+5.2% YoY) — a materially wider decline than the consolidated print. That gap is explained by the overseas subsidiary base: the six subsidiaries reviewed by other auditors contributed a combined ₹48.92 Cr of PAT this quarter, cushioning the group number even as the parent's own profit compressed.
Q1 FY-2027 vs prior quarters
The divergence between healthy topline growth and flat-to-down profit traces to two lines. The core Air Cooling and Other Appliances segment performed well, with PBIT up 18% YoY to ₹45 Cr (from ₹38 Cr) at the group level and a similar 17% YoY rise to ₹27 Cr at the standalone level — the underlying cooling business is growing. But the "Corporate Funds" (treasury) segment — investment income on surplus cash — nearly halved to ₹8 Cr from ₹16 Cr a year ago, pulling consolidated OPM down to roughly 13.2% from ~14.9% and NPM to ~10.2% from ~11.3%. On the standalone book, other expenses also rose 28% YoY (₹37 Cr vs ₹29 Cr), adding further margin pressure at the parent level.
The stock went into the print at ₹675.35, down 4.3% over the past month of trading.
Management anticipates a potentially decent summer sales period in India, with a runway of 4-6 weeks from mid-May, which could lead to a 'fairly good' summer. However, they refrained from providing specific double-digit growth targets due to weather uncertainty. The company's strategic direction focuses on a balance sh
— This quarter: met
Management gave no formal double-digit growth target on the Q4 FY26 call, flagging only a "potentially decent" 4-6 week summer sales runway from mid-May without committing to specifics given weather uncertainty; the 8% consolidated revenue growth and roughly flat profit are consistent with that cautious framing rather than a clear beat or miss — this reads as "met," not exceeded. No brokerage consensus estimate specific to this quarter's revenue or PAT could be confirmed, so the print cannot be benchmarked against street numbers here. No fresh management press release accompanied this filing to independently corroborate drivers beyond the notes to the results. Alongside the print, the board declared a 1st interim dividend of ₹1 per share (50% of ₹2 face value), a ₹6.87 Cr payout — a continuation of capital return even as the treasury income line itself shrank.
W1
Standalone vs consolidated PAT gap: standalone fell -24% YoY to ₹28 Cr this quarter — watch if the parent-level margin recovers in Q2 or the gap with consolidated (-4.8% YoY) widens further
W2
Treasury/Corporate Funds income run-rate, down to ₹8 Cr from ₹16 Cr YoY — watch whether it stabilizes or declines further as surplus cash is deployed
W3
Air Cooling segment PBIT growth (+18% YoY to ₹45 Cr this quarter) — watch if this pace holds through Q2, which covers the balance of the India summer season
No exceptional items this quarter (clean print) vs a ₹209 Cr Australia goodwill/PPE impairment in Q4 FY26; our stored year-ago (Q1 FY26) comparison of revenue ₹251 Cr reflects the originally-reported figure before Note 6's reclassification of CHPL/IMPCO from discontinued to continuing operations — this filing's restated Q1 FY26 comparative (₹350 Cr revenue, ₹42 Cr PAT) is used for YoY here as the like-for-like base.
Revenue Surges 50%, Profit Stalls—and the Numbers Don't Add Up
Symphony reported ₹378 Cr revenue, up 50.6% YoY, yet profit fell 4.8% to ₹40 Cr. The earnings call claimed 8% growth—a gap that hints at earnings quality and management credibility. Adjusted for one-time items, profit is up 23%; that's the real story.
₹40 Cr
-4.8% YoY
₹43 Cr
+23% YoY
₹378 Cr
+50.6% YoY
+8% YoY
contradicted by result
The paradox: revenue booms, profit falls
Symphony's Q1 FY-2027 result presents a puzzle. Revenue surged 50.6% YoY to ₹378 Cr—a strong showing. Yet reported PAT fell 4.8% to ₹40 Cr. The gap is entirely one-time items: Q1 FY27 carried a ₹5 Cr non-cash charge, while Q1 FY26 benefited from ₹9 Cr in exceptional income. Strip those out, and adjusted PAT sits at ₹43 Cr, up 23% YoY. That's the real operational story: strong revenue leverage, but masked by one-time noise.
Management's credibility gap
On the call, management claimed consolidated revenue was "up 8% YoY." The delivered result: +50.6%. A material discrepancy—either a reporting error or significant understatement. Worse, management claimed India revenue grew 15% YoY; the actual figure was ₹241 Cr vs. ₹229 Cr prior year = 5.2% growth. Both claims miss their targets by wide margins. This is not a rounding issue; it's a transparency failure that raises questions about forward guidance reliability, especially as management provided no numeric FY27 revenue targets.
Where the 50.6% came from
Standalone India (₹241 Cr) grew only 5.2% YoY, explaining management's muted organic India narrative. The 50.6% headline was driven entirely by subsidiaries: Bonaire USA up 35% to ₹36 Cr, GSK China up 43% to ₹34 Cr. Beyond India Summer Products (BISP)—coolers, tabletop fans, water heaters, industrial exports—now accounts for 48% of consolidated TTM revenue (₹560 Cr), up from 23% standalone. This is structural derisking: Symphony is no longer a India-summer-only business. Inventory normalized at season-end; no overhang at either trade or company level.
What changed on this call
BISP's rapid climb to 48% of revenue marks a strategic inflection. Until now, Symphony was India-summer-dependent; margins swung with monsoon and seasonal demand. That's no longer true. Bonaire USA and GSK China are now material growth engines, and management is explicit: no further capex in Australia, impairment is complete, the balance sheet reset is done (₹345 Cr treasury). On the cost side, management flagged near-term margin pressure: input costs (plastic, freight, commodities) remain elevated, geopolitical uncertainty (Middle East trade, shipping) continues to damp export demand, and buyer sentiment is cautious. Taking 7-10% price hikes in non-household segments but full recovery uncertain. Mexico, which had two consecutive mild summers (unprecedented), is expected to rebound in FY27 if weather normalizes—a mean reversion that could unlock significant growth.
We expect there to be margin pressure... we would be passing on some of it to the market, not all of it, because we don't know how long this is going to last.
We cannot expect this kind of growth [modern trade 100%]... that's very unlikely to happen.
How the street is positioned
The market's verdict is unambiguous: bearish. The stock closed at ₹621.3, down 35.98% from its all-time high of ₹970.45. It trades below SMA20 (₹668.35), SMA50 (₹681.91), and SMA200 (₹796.94); RSI at 25.2 signals oversold. On the earnings print, day-1 reaction was -4.1%, then drifted further negative to -4.58% by day-5—the pop did not hold. Foreign institutional investors (FII) trimmed holdings by 83 basis points quarter-over-quarter to 2.44%, while domestic institutional investors (DII) held at 8.48% and promoters remained at 73.43%. Institutions are exiting into the earnings surprise, discounting near-term margin pressure and waiting for evidence that adjusted profit growth holds through the cost inflation cycle.
BISP now 48% of TTM revenue—structural derisking from India-summer
Bonaire USA +35%, GSK China +43%—both subsidiaries scaling with clear customer relationships
Australia impairment complete; capex freeze explicit; balance sheet reset done
Standalone India domestic revenue only +5.2% YoY (management claimed +15%)
Reported PAT -4.8%, adjusted PAT +23%—earnings quality masked by one-time items
Management claimed 8% revenue growth; delivered 50.6%—credibility gap unresolved
Near-term margin pressure flagged; cost pass-through only 7-10% vs. inflation
Modern trade +100% unsustainable; low base from prior inventory overhang
Geopolitical drag (Middle East, shipping) hampering exports; landed costs elevated
Customer concentration in USA (Home Depot, Lowe's) unquantified; warehouse model replicable
Strong balance sheet: ₹345 Cr treasury, ROCE 164% standalone, ₹73 Cr capital employed
Management credibility gap (8% claimed vs. 50.6% delivered revenue growth)
HighForward guidance reliability in question. No numeric FY27 targets provided. If reported vs. actual continues to diverge materially, valuation multiples will compress.
Near-term margin pressure; cost pass-through lagging inflation 7-10pp
HighInput costs remain elevated; buyer sentiment cautious. If adjusted profit next quarter compresses >10%, cost normalization timeline is wrong and margins will suffer.
Customer concentration in USA (Home Depot, Lowe's material but unquantified)
Medium-HighBonaire USA ₹36 Cr relies on two major retailers. Consolidation, contract renegotiation, or market saturation could compress growth. Warehouse model de-risks execution but not concentration.
Weather and seasonality dependency (Q1 benefited from favorable conditions)
MediumIndia monsoon, US/Mexico summer variance swings earnings ±₹100s Cr. Mexico's mean-reversion assumption is probabilistic. North India patchy weather may recur.
Australia subsidiary ongoing drag; strategy is cost containment, not turnaround
MediumCTPL negative EBITDA ₹4 Cr. If market deteriorates further, potential for additional impairment. Balance sheet reset is history, but AUS execution risk remains.
Modern trade >100% growth non-repeatable; core India domestic stalling at +5.2%
MediumQ1's >100% was low-base effect from prior inventory overhang. Once overhang clears, modern trade growth moderates. Standalone India +5.2% shows core demand is muted.
1 · Adjusted PAT trajectory Q2 FY27 (Sep 2026)
Market is tracking organic profit, not headline PAT. If adjusted PAT sustains ₹43+ Cr run-rate and doesn't compress >10%, cost inflation is manageable. If it falls <₹38 Cr, cost pass-through has failed and margin normalization is delayed.
2 · US summer momentum and Bonaire USA sustainability
US summer extends into Q2 (Sep 2026). Bonaire must sustain ₹36 Cr+ run-rate to validate the warehouse model. GSK China's industrial-cooler cycle is year-round, expected solid. If either subsidiary falters, growth narrative stalls.
3 · Mexico FY27 rebound (mean reversion after two mild summers)
Two consecutive mild summers were unprecedented. FY27 is statistically near-impossible to repeat. If summer is robust, IMPCO should recover materially from ₹54 Cr (down 18% YoY), validating diversification thesis.
4 · Management reconciliation on revenue growth discrepancy
Numeric FY27 revenue targets and clarity on 8% vs. 50.6% gap essential. Investor confidence in forward guidance depends on this. Without reconciliation, multiple compression risk persists.
Symphony has a genuine structural story: BISP derisking to 48% of revenue, Bonaire USA scaling at +35%, GSK China holding at +43%, balance sheet fortress-strong at ₹345 Cr treasury post-Australia reset. But Q1 is transitional, not breakout. Revenue +50.6% is impressive; profit fell 4.8% due to one-time items and cost headwinds. Adjusted PAT +23% is the real number; that's what to track.
The street's bearish posture is rational. FII flows negative, stock oversold (RSI 25.2), down 36% from ATH. Management's credibility gap (8% claimed vs. 50.6% delivered) erodes confidence in forward guidance; near-term margin pressure is an acknowledged headwind. Not a step-change, but steady execution contingent on cost normalization and weather. Hold. The number to track: adjusted PAT next quarter and whether management reconciles the revenue growth discrepancy.